Evans R W, Manninen D L, Garrison L P, Maier A M
JAMA. 1986 Apr 11;255(14):1892-8.
Heart transplantation has now achieved a therapeutic status similar to that of cadaveric renal transplantation. Depending on patient selection criteria, it is estimated that as many as 15,000 people per year could conceivably benefit from a heart transplant, but the actual number of persons who will benefit is severely constrained by donor supply. Availability of heart donors was estimated based on data obtained on 1,955 organ donors in the United States. The results show that because of age and other contraindications, only 400 to 1,100 viable donor hearts may be available each year. Donor supply is the most critical determinant of the future of heart transplantation since it will dictate the number of transplants performed, the survival of transplant recipients, the total program expenditures associated with heart transplantation, the nature of the legal and ethical issues involved, the number of cardiac transplant programs required to make optimal use of the available donor hearts, and the future role of mechanical circulatory support systems.
心脏移植如今已达到与尸体肾移植相似的治疗地位。根据患者选择标准估计，每年可能有多达15000人有望从心脏移植中获益，但实际受益人数受到供体供应的严重限制。心脏供体的可获得性是根据在美国1955名器官供体上获得的数据估算的。结果表明，由于年龄和其他禁忌证，每年可能仅有400至1100颗可用的供体心脏。供体供应是心脏移植未来最关键的决定因素，因为它将决定所进行移植的数量、移植受者的存活情况、与心脏移植相关的总项目支出、所涉及法律和伦理问题的性质、为最佳利用可用供体心脏所需的心脏移植项目数量，以及机械循环支持系统的未来作用。
